Febuxostat - A new treatment for hyperuricaemia in gout - A review article

National Journal of Physiology, Pharmacy and Pharmacology

Volumn 2, Issue 1, 2012, Pages 23-28

  Pandey, Anjana ^a   Chaturvedi, Mridul ^a   Prakash, Himanshu ^a   Meena, Daulat ^a  

^a S N MEDICAL COLLEGE   (India)

Author keywords

Febuxostat; Gout; Hyperuricaemia; New treatment

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; COLCHICINE; DESIPRAMINE; FEBUXOSTAT; HYDROCHLOROTHIAZIDE; INDOMETACIN; MERCAPTOPURINE; NAPROXEN; THEOPHYLLINE; URATE; URIC ACID; WARFARIN; XANTHINE OXIDASE;

ABDOMINAL PAIN; CARCINOGENESIS; CARDIOVASCULAR DISEASE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; GOUT; HEADACHE; HEART REPOLARIZATION; HUMAN; HYPERTRANSAMINASEMIA; HYPERURICEMIA; INFERTILITY; MUSCULOSKELETAL DISEASE; MUTAGENESIS; NAUSEA; PHARMACODYNAMICS; PURINE METABOLISM; PURINE SYNTHESIS; PYRIMIDINE SYNTHESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 84950173793     PISSN: None     EISSN: 22313206     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol 2002; 14:281-286.
2. Loeb JN. The influence of temperature on the solubility of monosodium urate. Arthritis Rheum 1972;15:189-192
3. Allen DJ, Milosovich G, Mattocks AM. Inhibition of monosodium urate needle crystal growth. Arthritis Rheum 1965;8:1123-1133
4. Schlesinger N, Schumacher HR Jr. Gout: can management be improved? Curr Opin Rheumatol 2001; 13:240-244.
5. Harris MD, Siegel LB, Alloway JA. Gout and hyperuricemia. Am Fam Physician 1999; 59:925-934.
6. Fiddis RW, Vlachos N, Calvert PD. Studies of urate crystallisation in relation to gout. Ann Rheum Dis 1983; 42: Suppl 1:12-15.
7. Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF, Nishino T. An extremely potent inhibitor of xanthine oxidoreductase: crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem 2003; 278:1848-1855.
8. Khosravan R, Mayer M, Grabowski B, Vernillet L, Wu J-T, Joseph-Ridge N. Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase --effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety. Arthritis Rheum 2004; 50:S337-S337.
9. Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase, in subjects with renal impairment. Am J Ther 2005; 12:22-34.
10. Schumacher HR Jr, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009;48:188-194.
11. Schumacher HR et al, Arthritis & Rheumatism, 2008; 59:1540-1548
12. Susan P Bruce, Febuxostat: A Selective Xanthine Oxidase Inhibitor for the Treatment of Hyperuricemia and Gout The Annals of Pharmacotherapy 2006; 40:2187-2194
13. Okamoto K et al J Biol Chem. 2003;278:1848-1855
14. Michael A. Beckere et al(2006) Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and Gout. N Engl J Med 353:2450-2461